Advertisement
Screener

PROPANC BIOPHARMA, INC. (PPCB) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

2.8 / 5 stars · 68/120 Roast Me

PROPANC BIOPHARMA, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

PROPANC BIOPHARMA, INC. (PPCB) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $0 for the 6-month period ending 2016-12-31, per its 10-Q filed 2017-02-14.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-09-28

  • PROPANC BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
  • PROPANC BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $0.00.
  • PROPANC BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$9.20K.
  • PROPANC BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-03-31 was $0.00.
  • PROPANC BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$9.88K.
  • PROPANC BIOPHARMA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$5.58K.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed
2016-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14
$0.00
10-Q · filed 2017-02-14
-$9.20K
derived: sum of 3 quarters · filed 2017-09-28
-$9.20K
derived: sum of 4 quarters · filed 2017-09-28
2016-09-30$0.00
10-Q · filed 2016-11-10
-$9.20K
derived: sum of 2 quarters · filed 2017-09-28
-$9.20K
derived: sum of 3 quarters · filed 2017-09-28
-$9.20K
derived: sum of 4 quarters · filed 2017-09-28
2016-06-30-$9.20K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28
-$9.20K
derived: sum of 2 quarters · filed 2017-09-28
-$9.20K
derived: sum of 3 quarters · filed 2017-09-28
-$9.88K
10-K · filed 2017-09-28
-$12.06K
10-K · filed 2016-09-28
2016-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08
$3.00
derived: sum of 2 quarters · filed 2017-05-08
-$676.00
10-Q · filed 2017-05-08
2015-12-31$3.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14
-$676.00
10-Q · filed 2017-02-14
2015-09-30-$679.00
10-Q · filed 2016-11-10
2015-06-30-$5.58K
10-K · filed 2016-09-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
NANOVIRICIDES, INC. (NNVC)United States$0.031B
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45